Moxigram LX Eye Drops (Moxifloxacin + Loteprednol Etabonate )

• Composition :
  Moxifloxacin 0.5% + Loteprednol etabonate 0.5% Eye Drops.
• Indications :
  Postoperative steroid responsive inflammatory ocular infections or risk of bacterial ocular infections exists.
• Pharmacodynamics :
  The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.Loteprednol etabonate is a class of corticosteroid with potent antiinflammatory activity designed to be active at the site of action.
• Dosage and administration :
  One to two drops three times daily beginning 24 hours after surgery and continuing throughout the post-operative period for 2 weeks.
• Contraindications :
  Hypersensitivity to the active substance(s) or to any of the excipients. It is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
• Precautions and warnings :
  Topical ophthalmic use only.Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. Steroids should be used with caution in the presence of increased IOP, glaucoma. Cataract formation and delayed wound healing can happen with prolonged usage. Soft contact lenses should be avoided.
• Use in pregnancy, lactation & pediatrics :
  There are no adequate data from use during pregnancy, lactation and in infants.
• Drug interactions :
  Concurrent administration of cycloplegics may increase the risk of raised intraocular pressure.
• Adverse reactions :
  Decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, sub-conjunctival hemorrhage, tearing, optic nerve damage, visual acuity, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection.
• Therapy Area :
  Opthalmologicals